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Abstract: The study aimed to determine factors associated with changes in bone mineral density
(BMD) and bone resorption markers over two years in black postmenopausal women living with hu-
man immunodeficiency virus (HIV) on antiretroviral therapy (ART). Women (n = 120) aged > 45 years
were recruited from Potchefstroom, South Africa. Total lumbar spine and left femoral neck (LFN)
BMD were measured with dual energy X-ray absorptiometry. Fasting serum C-Telopeptide of Type I
collagen (CTx), vitamin D and parathyroid hormone were measured. Vitamin D insufficiency levels
increased from 23% at baseline to 39% at follow up. In mixed linear models serum CTx showed no
change from baseline to end (p = 0.363, effect size = 0.09). Total and LFN BMD increased significantly
over two years, but effect sizes were small. No significant change in spine BMD over time was
detected (p = 0.19, effect size = 0.02). Age was significantly positively associated with CTx over time,
and negatively with total and LFN BMD. Physical activity (PA) was positively associated with LFN
BMD (p = 0.008). Despite a decrease in serum vitamin D, BMD and CTx showed small or no changes
over 2 years. Future studies should investigate PA interventions to maintain BMD in women living
with HIV.
Keywords: HIV; calcium; bone mineral density; black; postmenopausal
1. Introduction
Ethnic differences in fracture risk exist, with Caucasians being at the highest risk for
fracture: i.e., several studies have shown that ethnicity could play a significant role in risk
for fragility fractures. However, most of this data emanates from populations in North
America and Europe. There are some data suggesting that black South African (SA) women
are at lower risk for fractures than white South African women, thought to be due to their
higher bone mineral density [1–7].
HIV-infected patients on antiretroviral therapy (ART) are experiencing an increased
life expectancy [8,9]. With this, a variety of potential health consequences arises. Studies
are showing the ubiquity of bone demineralization amongst HIV-infected patients [10–14].
The impact of HIV on bone health is considered to be complex and not yet fully under-
stood. HIV infection as well as ART leads to increased bone loss [15]. A variety of factors
contribute to the decreased bone mineral density (BMD) found within this group. These
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factors include traditional risk factors such as aging, a low body mass index (BMI), smok-
ing, alcohol use and dietary deficiencies. Additional disease and treatment specific risk
factors include chronic increased inflammation, immune reconstitution, opiate usage and
decreased testosterone levels [16].
A recent meta-analysis including 35 articles, with 17 of the articles including fracture
prevalence in HIV-infected patients and controls, indicated that HIV-infected patients had
a 4.08% prevalence for all fractures and a 2.66% prevalence for fragility fractures [17]. HIV-
infected patients were shown to have a higher prevalence for all fractures when compared
to control groups [17].
Achieving an optimal dietary calcium intake is known to be beneficial for the at-
tainment and maintenance of BMD [18]. However, Black SA women have a low calcium
intake [19]. An optimal calcium intake during late adolescence and early adulthood is
important as BMD peaks during these time periods [18]. When compared to the general
population, HIV-infected patients have a 58% higher fracture rate [20]; this may be due
to living longer with HIV and the cumulative exposure to ART with adverse effects on
bone health [21,22]. The initiation of ART and the possible associated bone loss will result
in an increase in the numbers of HIV-infected patients with decreased bone mass that
may increase fracture risk in these patients [21–24]. There are limited guidelines aimed at
preventing bone loss in people living with HIV (PLWH) [15].
There are sparse data from southern Africa on bone health in the HIV-infected patient
population. The data that are available are mainly limited to younger PLWH [25]. There
are no longitudinal studies of calcium intake and BMD in older HIV-infected women.
Therefore, the aim of this study was to determine the factors associated with BMD and a
bone resorption marker over a period of two years in black postmenopausal HIV-infected
women on ART.
2. Materials and Methods
2.1. Study Population
The study participants were recruited from outpatient clinics in Potchefstroom in
the North West Province, SA, where the majority of patients are of Tswana ethnicity
(nwpg.gov.za/nwglance.htm. Accessed on 14 June 2021). According to the inclusion
criteria, a total of 120 postmenopausal HIV-infected women, aged > 45 years on ART
were enrolled. Exclusion criteria include use of anti-osteoporotic agents and drugs known
to affect BMD (corticosteroids, thyroid medication, anti-vitamin K agents, diuretics, anti-
epileptic drugs, β-blockers); secondary causes of osteoporosis (chronic liver disease, chronic
obstructive pulmonary disease, chronic renal disease, immobility, rheumatoid arthritis,
gastrectomy, malabsorption syndromes); diagnosed diabetes mellitus; history of metabolic
bone disease; self-reported use of calcium and/or vitamin D supplementation, anti-acids
containing calcium; high alcohol consumption (≥3 units/day) and a fracture within the
last six months. Women with severely low BMD (T score < −3) at baseline could have been
enrolled, but were excluded and referred for medical treatment after baseline measurements.
A power calculation was performed using G-Power version 3.1.9.2 to estimate the
required sample size for this study. An estimated change in total BMD from 1.05 to
1.0 g/cm2 in the group (difference 0.05) and a standard deviation (SD) of 0.11 g/cm2 were
used, with 80% power and a 5% level of significance. The estimated difference between
the change in total body BMD and SD are based on existing data from a cross-sectional
study in HIV-positive black women studied in 2014 in the North West Province [26]. The
power calculation indicated that for group comparisons (lowest versus highest values of
variables), 53 women per group would be sufficient to show a difference of 0.05 g/cm2.
2.2. Data Collection
Data was collected at baseline and at one and two years of follow-up. Baseline and
follow-up visits were scheduled over time until all measurements had been completed at
the metabolic unit of North-West University.
Nutrients 2021, 13, 2090 3 of 12
2.3. Measurements
Socio-demographic and health information of the women (age, educational status,
housing, occupation, smoking, alcohol consumption, chronic medication) was obtained
by an interviewer-administered structured questionnaire, used previously in a group
with a similar age range in the prospective urban rural epidemiology (PURE) study [27].
Time period since diagnosis and since initiation of ART was also self reported by the
participants. Anthropometric measurements (height, weight, waist circumference, mid-
upper arm circumference, calf circumference) were performed by trained postgraduate
Nutrition students using standard methods with participants wearing light clothing [28].
Height (cm) was measured to the nearest 0.1 cm with the participant barefoot and with
the head in the Frankfort plane, and weight was measured to the nearest 0.01 kg on an
electronic scale and stadiometer (Seca model 284, Hamburg, Germany). BMI was calculated
as weight (kg) divided by height (m) squared [27]. Waist circumference was measured
using a flexible steel tape (Lufkin, Cooper tools, Apex, NC, USA) around the waist at the
level of minimal girth between the lower rib and iliac crest, to the nearest 0.1 cm. Mid-upper
arm circumference (MUAC) was measured using a flexible steel tape to the nearest 0.1 cm
on the participant’s left arm. Calf circumference was measured in a similar way at the
medial surface, at the level of the largest circumference.
Dietary intake was assessed at baseline and at one-year follow-up by trained field-
workers using a standardised quantitative food frequency questionnaire, a validated
food portion photo book and food models to estimate portion sizes and convert intakes to
weight [29–32]. Nutrient intake was calculated using the SA food composition database [33].
Physical activity (PA) was assessed at the same visits by a trained fieldworker using the
Global Physical Activity Questionnaire (GPAQ) recommended by the World Health Orga-
nization (WHO) [34].
BMD was measured by a registered radiographer through dual energy x-ray absorp-
tiometry (DXA) with the default Hologic settings (Hologic Discovery W, APEX system
software version 2.3.1): total body, lumbar spine and left femoral neck (LFN) hip, at base-
line, and at one- and two-year follow-up visits. The coefficient of variation (CV) of the
femoral neck ranged between 1.1% and 1.2% and the CV for the lumbar spine BMD ranged
between 0.7% and 0.9%. Verbal feedback was given to each participant at each measure-
ment date. Participants were required to wear a cotton gown without any metal trimmings
and all jewellery was removed.
Fracture risk was assessed using a checklist developed from information in the liter-
ature [35,36]. The checklist included eleven fracture risk factors: age > 40 years, female
sex, underweight (BMI < 18.5 kg/m2), previous fractures, parent fractured hip, currently
smoking, glucocorticoid therapy and proton pump inhibitor use during the last six months,
rheumatoid arthritis, secondary osteoporosis and alcohol consumption of ≥3 units per
day. Currently no validated fracture risk instrument is available for South African popula-
tions. The number of risk factors was recorded and represents the sum of the fracture risk
conditions present in each participant.
2.4. Blood Analyses
All blood samples were collected in serum tubes and centrifuged as soon as possible
after sample collection. Serum was prepared and stored in a bio freezer at −80 ◦C. Fasting
serum concentrations of a bone resorption marker, C-Telopeptide of Type I collagen (CTx,
B-CrossLaps/serum Elecsys Cobas e100), serum vitamin D (25(OH)D), Vitamin D total
Elecsys Cobas) and parathyroid hormone (PTH, PTH Elecsys Cobas e100) were measured
by immunoassay (Roche Diagnostics Pty (Ltd.), Johannesburg, South Africa). All samples
were analysed together in one batch with the same controls for each year of measurement.
Serum 25(OH)D, PTH and CTx were measured at baseline, and again at one- and two-year
follow-up visits. A serum 25(OH)D concentration of <20 ng/mL was used to classify
vitamin D status as being deficient, 20–29 ng/mL as insufficient and ≥30 ng/mL as
sufficient [37,38]. The intra-assay coefficients of variation (CV) were 3.8% for vitamin
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D, 1.2% for PTH and 2.4% for CTx. The inter-assay CVs were 16.3%, 8.1% and 10.3%
respectively.
2.5. Statistical Methods
Data was tested for a normal distribution with the Shapiro–Wilk test and QQ plots.
Descriptive statistics of socio-demographic data, dietary intakes, PA, BMD at the different
sites (baseline), 25(OH)D, as well as PTH and the bone resorption marker CTx, were pre-
sented as means and SD (data with normal distribution) or median and interquartile range
(non-normal distribution). Variables with a non-normal distribution were logarithmically
transformed and the distribution of the transformed variables was assessed. Changes in
the outcomes (BMD of the total body, lumbar spine and LFN of the hip, CTx and 25(OH)D
from baseline to end were assessed by mixed linear models. Changes in PTH (non-normal
distribution even after log transformation) were tested by the Wilcoxon signed rank test.
Associations between variables were explored with Pearson (normal distribution) and
Spearman correlation analysis (non-normal distribution). Differences between outcome
variables of smokers and non-smokers were compared using the Mann–Whitney test.
Linear mixed models were used with CTx and BMD, respectively, as the dependent
variables (outcomes) and dietary calcium intake as the primary exposure, with adjustment
for variables identified to correlate with the exposure or outcomes (age, household income,
education level, PA level). Separate models were used for whole body BMD, spine BMD
and LFN BMD, respectively. Time was treated as a fixed effect and participant as random
effect. The restricted maximum likelihood (REML) approach was used as a likelihood
function calculated from the residuals obtained after adjusting for the fixed effects. The
unstructured covariance structure was applied.
Statistical analyses were performed using the SPSS version 26 statistical software
program. The level of significance was set at p ≤ 0.05.
3. Results
The demographic information of the participants is summarised in Table 1. Initially,
a total of 120 postmenopausal women were included at baseline. After 1 year, drop outs
were due to death (5), refusal to follow up (3) and untraceable (13). After 2 years, the drop
outs were due to death (8), refusal to follow up (3) and untraceable (5), as indicated in
Figure 1. Our participants had HIV infection for a mean duration of 10 years (±5.12) and
received ART treatment for 9 years (±4.79)
Table 1. Study participants’ characteristics from baseline to 2-year follow-up.









Median (IQR) Median (IQR) Median (IQR)
Age (years) 50 (48–55) 51 (49–56) 52 (50–57)
Weight (kg) 66.6 (54.1–80.0) 68.1 (57.9–83.0) 67.6 (54.8–83.9)
Height (cm) 156.6 (151.5–161.0) 157.5 (152.3–161.5) 156.7 (151.8–160.4)
BMI (kg/m2) 27.1 (22.4–32.6) 28.4 (23.5–32.2) 28.3 (23.0–33.2)
Waist circumference (cm) 85.0 (76.0–97.3) 88.6 (76.9–96.6) 90.8 (76.7–101.0)
Calf circumference (cm) 33.9 (30.0–37.5) 34.4 (30.7–37.6) 33.9 (30.2–37.7)
Mid-upperarm circumference (cm) 31.6 (28.0–34.4) 31.6 (27.6–34.1) 31.3 (27.3–33.7)
Total BMD (g/cm2) 1.04 (0.95–1.12) 1.04 (0.98–1.14) 1.03 (0.96–1.11) 0.02
Spine BMD (g/cm2) 0.84 (0.75–0.95) 0.88 (0.79–0.98) 0.87 (0.78–0.97) 0.19
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Table 1. Cont.









Median (IQR) Median (IQR) Median (IQR)
LFN BMD (g/cm2) 0.74 (0.65–0.84) 0.73 (0.65–0.84) 0.76 (0.68–0.86) 0.0001
Lean mass (kg) 37.0 (32.9–42.6) 38.5 (33.8–45.2) 37.7 (34.0–45.6)
Percent body fat mass (%) 38.6 (33.8–43.6) 39.1 (33.3–42.8) 39.9 (33.4–43.6)
Serum 25(OH)D (ng/mL) 36.6 (28.1–44.2) 31.5 (25.0–41.1) 30.1 (24.9–37.6) <0.0001
PTH (pg/ml) 41.3 (33.02–58.2) 42.9 (31.7–57.1) 47 (36.9–62) 0.08
CTx (ng/ml) 0.48 (0.35–0.75) 0.48 (0.35–0.65) 0.48 (0.34–0.69) 0.36
Dietary intake -
Ca-intake (mg/d) 668.3 (413.2–911.9) 517.6 (352.3–794.1)
Energy (kJ) 10247 (7680–12514) 9330 (6166–11247) -
Fat (g) 76.6 (50.0–100.0) 57.1 (44.5–84.2) -
Protein (g) 75.6 (57.1–93.6) 68.9 (51.0, 96.5) -
Alcohol- intake (g/d) 0.0 (0.0–0.86) 0.0 (0.0–1.3) -
Physical activity (PA)
PA (MET min/week) 2880 (960–7190) 2970 (840–6740) 3240 (2040–4530)
Sedentary
Time (min/day) 240 (150–375) 240 (150–375) 240 (180–360)
n (%) n (%) n (%)
1st line ART (FTC; TDF; EFV) 105 (87.5) 81 (81.8) 84 (80.8)
2nd line ART (AZT; 3TC; LPV/r) 15 (12.5%) 18 (18.2) 20 (19.2)
Vitamin D status
Deficiency 12 (10.2) 14 (14.3) 12 (11.5)
Insufficiency 23 (19.5) 28 (28.6) 39 (37.5)
Sufficiency 83 (70.3) 56 (57.1) 53 (51.0)
Education
No school & primary 44 (36.7) 29 (29.3) 31 (29.8)
Grade 8–11 44 (36.7) 40 (40.4) 43 (41.3)
Grade 12 31 (25.8) 29 (29.3) 29 (27.9)
Tertiary 1 (0.8) 1 (1.0) 1 (1.0)
Income (per month)
None 6 (5.0) 3 (3.0) 10 (9.6)
<R500–R1000 31 (12.5) 21 (21.2) 14 (13.5)
R1001–R6000 74 (61.7) 64 (64.6) 72 (69.2)
>R6000 9 (7.5) 11 (11.1) 7 (6.7)
Hypertension 55 (45.8) 46 (46.5) 48 (46.1)
Diabetes mellitus 10 (8.3) 9 (9.1) 8 (7.7)
BMI = body mass index; BMD = body mass index; PTH = parathyroid hormone; CTx = C-Telopeptide of Type I collagen; Ca = calcium;
MET = metabolic equivalent; 3TC (lamivudine); TDF (tenofovir); EFV (efavirenz) FTC (emtricitabine). * Changes from baseline to end
determined by linear mixed modelling (in participants with data at all three data points).
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 Median (IQR) Median (IQR) Median (IQR)  
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Weight (kg) 66.6 (54.1–80.0) 68.1 (57.9–83.0) 67.6 (54.8–83.9)  
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Fig re 1. er f rtici ts er e r r out reasons.
The revalence of vitamin D deficiency and insufficiency increased over the two years
and median serum 25(OH)D concentrations decreased, whereas serum PTH showed a
trend of an increase. Alcohol intake within the group was low. A small percentage of our
group reported being current smokers (14%), with a median of 2 cigarettes per day. PA
increased from baseline to 2 year follow up, but sedentary time remained consistent over
time. The most common fracture risk factors at baseline were age and female sex (100%
of participants), followed by previous fracture and currently smoking (both 14.2%). The
highest number of risk factors present was five out of a maximum of 11 (5% of women).
Six women developed incident fragility fractures at the 1-year follow-up and an additional
four reported new fragility fractures at the 2-year follow-up. The proportion of current
smokers decreased over the two years from 14.2% to 11.9%.
Spine, total and hip BMD, CTx, PTH and vitamin D showed no differences between
smokers and non-smokers. Correlation analysis is presented in Table 2. There was a
positive correlation between age and PTH (r = 0.20, p = 0.03), but no correlation between
PTH, or 25(OH)D, respectively, with BMD at any site, or CTx. There was no correlation
between the number of fracture risk variables present per participant and any of the BMD
variables, or CTx.
Table 2. Spearman and Pearson correlations between age and lifestyle and bone variables.
Variable HH Income PA LFN BMD Total SpineBMD Total BMD CTx
Spearman correlations
r p r p r p r p r p r p
Age −0.03 0.711 −0.06 0.503 −0.38 <0.0001 −0.28 0.002 −0.41 <0.0001 0.30 0.001
Pearson correlations
Serum vit D 0.001 0.990 −0.003 0.970 0.000 0.999
HH = household; PA = physical activity; LFN = left femoral neck; BMD = bone mineral density; CTx = C-Telopeptide of Type 1 collagen.
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In mixed linear models serum CTx (log transformed) showed no change from baseline
to end (p = 0.363, effect size = 0.09). Total BMD increased significantly from baseline to the
1-year follow-up (p = 0.02), but not to the 2-year follow-up. The effect size of the change
over time in total BMD was small (0.03). Similarly, LFN BMD increased significantly over
two years, but with a small effect size (0.06), while there was no significant change in
spine BMD over time (p = 0.19, effect size = 0.02). Serum 25(OH)D concentration showed
a significant decline from baseline through to year 2 follow-up (p < 0.0001) with an effect
size of 0.39. There were no significant changes in PTH from baseline over the two years
(p = 0.08), but a clear trend of an increase over time (p = 0.08).
In subsequent linear mixed models, age was significantly positively associated with
log CTx over time, and negatively with total and LFN BMD (Table 3). Total PA had a weak
positive association with LFN BMD over time (β = 0.0003, p = 0.008). Calcium intake was
not associated with any outcomes from baseline to end, with only spine BMD showing a
weak trend of a positive association. The Bayesian information criterion (BIC) is indicated
for the goodness of fit of the different models.
Table 3. The association between bone health variable and lifestyle and dietary factors (linear mixed models).
Parameter Log CTx Total BMD Spine BMD LFN BMD
Estimate p Estimate p Estimate p Estimate p
Time 0.04 0.051 −0.02 0.003 −0.50 0.129 0.002 0.799
Age 0.01 0.009 −0.01 <0.0001 0.07 0.02 −0.01 <0.0001
Education −0.02 0.45 0.009 0.501 0.12 0.509 0.003 0.792
PA 0.0003 0.24 0.0002 0.093 −0.0002 0.583 0.0003 0.008
Calcium −0.0005 0.25 −0.0001 0.410 0.0007 0.123 −0.0004 0.770
Bayesian information
criterion 5.39 −299.5 831.6 −274.1
PA = physical activity; BMD = Bone mineral density; LFN = Left femoral neck; CTx = C-Telopeptide of Type 1 collagen.
4. Discussion
The main findings of this study are that time, age, and PA are associated with BMD.
Total BMD as well as LFN BMD increased significantly over the two year time period;
however, the effect size remained small. Spine BMD and serum CTx showed no change
over the two year time period. It is important to note that the effect size for changes in
both total BMD and LFN BMD were small, and therefore probably not clinically relevant.
We considered calcium intake, PA, age, educational status, serum vitamin D, PTH, alcohol
intake, as well as smoking as possible factors that could be associated with BMD and a
bone resorption maker in our study participants, but only age and PA were shown to
have associations (with LFN BMD). A recent study contested the idea of genetic protection
against osteoporosis at all skeletal sites in black SA women [7].
We found a small, but significant, increase in total BMD from baseline to 1-year follow-
up, but this change was not maintained at the 2-year follow up. LFN BMD also showed a
small increase over the two years, while spine BMD and serum CTx showed no change
over the two years. It is important to note that the effect size for changes in both total BMD
and LFN BMD were small, and therefore not clinically relevant. An important observation
to make is that the decline in BMD was slow. The small changes in BMD at all sites must
be seen in the context of decreased vitamin D levels, trend of increased PTH levels and a
dietary calcium intake < 800 mg/day, all of which would have attenuated any potential
increases in BMD. Hamill and co-workers [37] reported slightly higher BMD values in
urban, black premenopausal HIV-positive women who were ART-naïve than what we
found in our study (hip BMD = 0.988, LFN BMD = 0.923, lumbar spine BMD = 1.006). This
difference could be attributed to the participants being younger in age (premenopausal).
Another study found that low BMD was significantly more frequent in HIV-positive women
compared to women without HIV [39]. Although there was no decrease in BMD over the
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two years of follow-up, 8.3% of the women reported incident fragility fractures over the
two years of follow-up.
HIV infection, as well as ART are known to result in increased bone loss [40]. Mondy
and co-workers [41] found that a decreased body weight, smoking and a long period of
HIV infection (≥17 years) were primary factors associated with a low BMD. Our study
participants reported a shorter mean duration of HIV infection (mean of 10 years) and
therefore, it was possibly not long enough to show the same effect. Several studies have
shown a high prevalence of low BMD in HIV-positive persons. These studies were, however,
primarily based on participants with a lean or normal BMI [12,42,43]. The majority of our
participants were overweight or obese, with no indications of weight loss over the three
time-points of observation. This confirms the protective effect that body weight has on the
prevention of bone loss. Conradie and co-workers (2014) [7] also found that the decreased
loss of bone found in black women was related to a progressive increase in body weight in
aging black women.
Biochemical markers of bone turnover are considered potential predictors of fractures.
This is due to their interrelationship to bone quality as well as bone quantity [44,45].
Population-based studies have indicated that an increased bone turnover is associated with
an increased risk of osteoporotic fractures. However, in our study, serum CTx showed no
change over a period of two years. In the linear mixed models, we found that age was
positively associated with log CTx over time, and negatively with total as well as LFN
BMD. Higher levels of CTx were reported in a study conducted in non-HIV-infected black
postmenopausal SA women than in the present study, and this was significantly associated
with an increased loss of BMD over a two year period at the distal radius [46].
Bone turnover is either activated through mechanical stimuli on the bone or through
systemic changes in homeostasis, resulting in the production of oestrogen and PTH [47].
PTH is considered to be necessary for the preservation of serum calcium concentrations [48].
The action of PTH on the osteoblastic lineage cells results in both the differentiation and
the activation of osteoclasts, which leads to bone degradation as well as initiation of the
resorption phase [49]. We found a trend of an increase in serum PTH over two years, in line
with a significant decrease in serum 25(OH)D over the same time. This observation confirms
the inverse relationship known to exist between vitamin D and PTH [50]. One to four
percent of the variation found in PTH levels can be explained by vitamin D status [50,51].
Patients with secondary hyperparathyroidism are also known to have increased levels of
PTH in response to low levels of serum 25(OH)D [37,52,53].
There was a gradual increase in the percentage body fat mass over the 2-year obser-
vational period. A large portion of the women included in this study were also classified
as overweight according to their BMI. A recent study found that postmenopausal women
with a higher BMI (>27 kg/m2) had lower levels of 25(OH)D [54]. This is similar to the
results of our study, as serum 25(OH)D decreased over the observational period. This
decrease in 25(OH)D concentration could be associated with the increase of fat mass.
Dietary calcium is known to play an important role in bone health [55,56]. Within
this group, calcium intake was not significantly associated with any of the outcomes. The
lack of association between variables could be an indication that our follow-up duration
was not sufficient to detect any associations. Urbanisation is known to be associated with
lower calcium intake in black SA women [57]. Furthermore, lower consumption of milk
and dairy products was found in urban women when compared to rural women in a SA
study [57]. Another possibility to take into account is that our group could have been under-
or over-reporting on calcium-rich food intakes. A study conducted by Pedrera-Zamorano
and co-workers [56] found that the protective effect of calcium on bone might possibly not
be noticeable in postmenopausal women with a calcium intake lower than 800 mg/day. A
study conducted in a similar population group also found participants to have low calcium
intakes, with only 19.6% of the participants reaching an intake higher than 800 mg/day [58].
Ensuring a dairy intake of at least two cups per day (500 mL) has been shown to lower the
incidence of osteoporosis as well as associated fractures [59].
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PA showed a significant positive association with LFN BMD across the study duration
(2 years). PA within this population group may reflect lifelong PA, which is unlikely
to change or improve over time. The literature shows differing results regarding the
association between PA and bone health. The discrepancies in results may be due to
disparity in measurements of PA as well as population groups [60,61]. Studies in high
risk population groups such as postmenopausal women have found that PA improved
BMD as well as decreased fracture risk [62–64]. Limited data is available on the impact
of PA on BMD in people living with HIV, however it is expected that PA will produce
similar benefits [65–67]. A study conducted by Perazzo and co-workers [66] found that, in
a group of relatively healthy HIV-infected participants on stable ART, those that reached
the recommended level of PA, had increased BMD levels at the total hip in comparison to
those not meeting this level of PA.
Limitations of this study include the observational design of the study and the lack of a
HIV-uninfected control group, resulting in the inability to attribute causation. Participants
originated from a segmented area in Potchefstroom, in the North West Province therefore
extrapolation to other population groups should be carried out with caution. It is also
important to note that the participant group for this study was small, which could have
impacted overall results. Other limitations include the lack of information on years since
menopause and that no bone formation markers, such as P1NP were measured due to lack
of funding. Despite these limitations, our findings add to the existing body of evidence
on calcium intake and serum vitamin D concentration in relation to changes in BMD over
time within this population group.
5. Conclusions
In conclusion, this study found practically insignificant increases in total and LFN
BMD over a 2-year follow up, while spine BMD and serum CTx showed no change over
the two years. It could be beneficial to have a longer study duration to determine if
any differences will appear in the outcomes. Future studies should also investigate the
association between PA and LFN BMD and interventions to strengthen these outcomes.
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